MedStar Authors catalog › Details for: Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.
Normal view MARC view ISBD view

Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.

by Lipinski, Michael J; Pendyala, Lakshmana K; Torguson, Rebecca; Chen, Fang; Waksman, Ron.
Citation: Atherosclerosis. 235(2):295-8, 2014 Aug..Journal: Atherosclerosis.ISSN: 0021-9150.Full author list: Lipinski MJ; Pendyala LK; Torguson R; Chen F; Waksman R.UI/PMID: 24908239.Subject(s): Aged | *Diabetes Mellitus, Type 2/dt [Drug Therapy] | Drug-Eluting Stents/ae [Adverse Effects] | Female | Humans | Male | *Metformin/tu [Therapeutic Use] | Middle Aged | Paclitaxel/ad [Administration & Dosage] | *Percutaneous Coronary Intervention | *Stents/ae [Adverse Effects] | *Thrombosis/ci [Chemically Induced]Institution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal Article | Observational StudyOnline resources: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.919 (Click here) Abbreviated citation: Atherosclerosis. 235(2):295-8, 2014 Aug.Abstract: OBJECTIVE: Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis. Therefore, we assessed the impact of metformin on stent thrombosis and major adverse cardiovascular events (MACE) in non-insulin-dependent diabetes mellitus (NIDDM) patients who receive drug-eluting stents (DES).Abstract: METHODS: We assessed the impact of metformin and stent type on stent thrombosis, MACE, and death in NIDDM patients following DES placement. Of the 1201 patients included, 74.8% received LES, 25.2% received paclitaxel-eluting stents (PES), and 55% were taking metformin.Abstract: RESULTS: There was no difference in stent thrombosis, regardless of stent type or metformin use. While Kaplan-Meier curves demonstrated reduced MACE (p = 0.007) and death (p = 0.006) with metformin use, multivariate analysis demonstrated that stent type and metformin use were not associated with outcome.Abstract: CONCLUSION: In NIDDM patients, metformin use or stent type following DES placement did not increase stent thrombosis and MACE rates.Copyright � 2014 Elsevier Ireland Ltd. All rights reserved.

Powered by Koha